The prognostic impact of human epidermal growth factor receptor 2 (HER2) status in metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Starling, N. [1 ]
Snider, J. [2 ]
Cho-Phan, C. [2 ]
Wang, J. [2 ]
Martin, P. [3 ]
Simon, C. [3 ]
Bartley, K. [4 ]
机构：
[1] Royal Marsen NHS Fdn Trust, Gastrointestinal Unit, Surrey, England
[2] Flatiron Hlth, New York, NY USA
[3] Pfizer Inc, Med Affairs, Sandwich, Kent, England
[4] Pfizer Inc, Hlth Econ & Outcomes Res, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
75P
引用
收藏
页码：S36 / S37
页数：2
相关论文
共 50 条
  • [21] Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
    Sarkis, Julien
    Alkassis, Marwan
    Assaf, Joy
    ARAB JOURNAL OF UROLOGY, 2020, 18 (04) : 273 - 274
  • [22] Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas
    Clauditz, Till Sebastian
    Reiff, Maren
    Gravert, Linn
    Gnoss, Alexander
    Tsourlakis, Maria-Christina
    Muenscher, Adrian
    Sauter, Guido
    Bokemeyer, Carsten
    Knecht, Rainald
    Wilczak, Waldemar
    PATHOLOGY, 2011, 43 (05) : 459 - 464
  • [23] Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies
    Erickson, Britt K.
    Zeybek, Burak
    Santin, Alessandro D.
    Fader, Amanda N.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2020, 32 (01) : 57 - 64
  • [24] Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
    Riecke, Kerstin
    Witzel, Isabell
    BREAST CARE, 2020, 15 (06) : 579 - 585
  • [25] Draft recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer will decrease HER2 positivity rates
    Johnson, Eric
    Gulbahce, Evin
    CANCER RESEARCH, 2018, 78 (04)
  • [26] Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas
    Fassan, Matteo
    Ludwig, Kathrin
    Pizzi, Marco
    Castor, Carlo
    Guzzardo, Vincenza
    Balistreri, Mariangela
    Zaninotto, Giovanni
    Ruol, Alberto
    Giacomelli, Luciano
    Ancona, Ermanno
    Rugge, Massimo
    HUMAN PATHOLOGY, 2012, 43 (08) : 1206 - 1212
  • [27] Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma
    Togami, Shinichi
    Sasajima, Yuko
    Oi, Takateru
    Ishikawa, Mitsuya
    Onda, Takashi
    Ikeda, Shun-Ichi
    Kato, Tomoyasu
    Tsuda, Hitoshi
    Kasamatsu, Takahiro
    CANCER SCIENCE, 2012, 103 (05) : 926 - 932
  • [28] Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
    Raghav, Kanwal
    Loree, Jonathan M.
    Morris, Jeffrey S.
    Overman, Michael J.
    Yu, Ruoxi
    Meric-Bernstam, Funda
    Menter, David
    Korphaisarn, Krittiya
    Kee, Brian
    Muranyi, Andrea
    Singh, Shalini
    Routbort, Mark
    Chen, Ken
    Shaw, Kenna R. M.
    Katkhuda, Riham
    Shanmugam, Kandavel
    Maru, Dipen
    Fakih, Marwan
    Kopetz, Scott
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 13
  • [29] Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)
    Seyedmirzaei, Homa
    Keshavarz-Fathi, Mahsa
    Razi, Sepideh
    Gity, Masoumeh
    Rezaei, Nima
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1235 - 1244
  • [30] Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer
    Awada, Gil
    Gombos, Andrea
    Aftimos, Philippe
    Awada, Ahmad
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (01) : 91 - 101
12345